| Drug Name |
Triazolam |
| Drug ID |
BADD_D02277 |
| Description |
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances. |
| Indications and Usage |
For the short-term treatment of insomnia. |
| Marketing Status |
approved; investigational |
| ATC Code |
N05CD05 |
| DrugBank ID |
DB00897
|
| KEGG ID |
D00387
|
| MeSH ID |
D014229
|
| PubChem ID |
5556
|
| TTD Drug ID |
D0U3LS
|
| NDC Product Code |
12828-0041; 0009-0017; 50090-6471; 59762-3717; 43353-451; 70710-1521; 71335-1876; 0009-5188; 42816-0017; 67763-128; 0054-4858; 50742-645; 43063-996; 50742-646; 59762-3718; 70710-1289; 70771-1576; 50090-4733; 70771-1162; 0054-4859 |
| UNII |
1HM943223R
|
| Synonyms |
Triazolam | U-33,030 | U 33,030 | U33,030 | Halcion | Trilam | Apo-Triazo | Apo Triazo | Gen-Triazolam | Gen Triazolam |
